Saira Iqbal
Saira Iqbal has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Fahad Amin
King Edward Medical University, Lahore, Pakistan
3 shared publications - Rija Fatima
King Edward Medical University , Lahore
3 shared publications - Abdul Rehman Azam
King Edward Medical University, Lahore, Pakistan
1 shared publication - Amna Raza
Akhtar Saeed Medical and Dental College, Lahore, Pakistan
1 shared publication - Ayesha Aman
King Edward Medical University , Lahore
1 shared publication - Esha Naeem
King Edward Medical University, Lahore, Pakistan
1 shared publication
Latest Publications
- 13 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
Janus Kinase inhibitors in refractory Takayasu arteritis: a systematic review and proportion meta-analysis of efficacy and safety
Objectives: Takayasu arteritis (TAK) is a rare chronic granulomatous vasculitis affecting large arteries, causing recurrent disease despite standard treatment. This systematic review and meta-analysis aimed to evaluate efficacy and safety of Janus kinase inhibitors in patients with refractory Takayasu arteritis. Methods: We searched five major databases from inception through July 16, 2026, for observational cohorts, non-randomized interventional studies, and case series including ≥5 patients. Eligible studies enrolled adults with refractory TAK treated with JAK inhibitors. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane ROBINS-I and Joanna Briggs Institute tools. The protocol was registered in PROSPERO (CRD420261469541). GRADE was used to assess certainty of primary efficacy outcomes. Results: Eleven studies comprising 185 patients were included. The pooled clinical remission rate was 64% (95% CI, 55%–72%; I²=0%), while complete and partial remission rates were 65% (95% CI, 55%–74%) and 8% (95% CI, 4%–17%), respectively. Pooled rates of no response and relapse were 24% and 14%, respectively. Imaging improvement or stabilization was observed in 44% of patients, while glucocorticoid-sparing effects occurred in 56%. Adverse events occurred in 10% of patients, and 7% discontinued treatment because of adverse events. GRADE certainty was very low for all assessed outcomes. Conclusion: JAK inhibitors demonstrate promising clinical efficacy and a potentially manageable safety profile in refractory TAK. However, the available evidence is predominantly observational and therefore subject to confounding and other sources of bias. High-quality prospective and randomized studies are needed to establish their efficacy, comparative effectiveness, and long-term safety.
- 13 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
Janus Kinase inhibitors in refractory Takayasu arteritis: a systematic review and proportion meta-analysis of efficacy and safety
Objectives: Takayasu arteritis (TAK) is a rare chronic granulomatous vasculitis affecting large arteries, causing recurrent disease despite standard treatment. This systematic review and meta-analysis aimed to evaluate efficacy and safety of Janus kinase inhibitors in patients with refractory Takayasu arteritis. Methods: We searched five major databases from inception through July 16, 2026, for observational cohorts, non-randomized interventional studies, and case series including ≥5 patients. Eligible studies enrolled adults with refractory TAK treated with JAK inhibitors. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane ROBINS-I and Joanna Briggs Institute tools. The protocol was registered in PROSPERO (CRD420261469541). GRADE was used to assess certainty of primary efficacy outcomes. Results: Eleven studies comprising 185 patients were included. The pooled clinical remission rate was 64% (95% CI, 55%–72%; I²=0%), while complete and partial remission rates were 65% (95% CI, 55%–74%) and 8% (95% CI, 4%–17%), respectively. Pooled rates of no response and relapse were 24% and 14%, respectively. Imaging improvement or stabilization was observed in 44% of patients, while glucocorticoid-sparing effects occurred in 56%. Adverse events occurred in 10% of patients, and 7% discontinued treatment because of adverse events. GRADE certainty was very low for all assessed outcomes. Conclusion: JAK inhibitors demonstrate promising clinical efficacy and a potentially manageable safety profile in refractory TAK. However, the available evidence is predominantly observational and therefore subject to confounding and other sources of bias. High-quality prospective and randomized studies are needed to establish their efficacy, comparative effectiveness, and long-term safety.
- 10 July 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (8)
Therapeutic equivalence of intermittent and continuous phototherapy for neonatal jaundice: a systematic review & meta-analysis with regression and trial sequential analysis
Phototherapy is the mainstay treatment for neonatal hyperbilirubinemia, but the optimal delivery strategy remains debated. Intermittent phototherapy (IMPT) has been proposed as an alternative to continuous phototherapy (CPT) that may achieve comparable bilirubin reduction with fewer adverse effects. This systematic review and meta-analysis evaluated the comparative efficacy and safety of IMPT versus CPT in neonates with hyperbilirubinemia. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched through June 2026 for randomized controlled trials comparing IMPT and CPT. Outcomes included rate of fall in bilirubin, follow-up bilirubin, phototherapy duration, hospital stay, and mortality. Random-effects meta-analysis pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Subgroup, meta-regression, and Trial Sequential Analysis (TSA) were performed, and certainty of evidence was graded using GRADE. Twenty-six RCTs (3,891 neonates) were included. No significant difference was found between IMPT and CPT for rate of bilirubin fall, follow-up bilirubin, hospital stay, or mortality. IMPT significantly reduced phototherapy duration (MD - 10.40 h, 95% CI - 18.91 to - 1.88). Heterogeneity was substantial across outcomes. TSA indicated conclusive evidence of equivalence for bilirubin-related and hospital stay outcomes, while evidence for the duration reduction had not yet reached the required information size. Certainty of evidence ranged from low to very low. IMPT achieves outcomes comparable to CPT while significantly reducing treatment duration, supporting its use as a time-efficient alternative, though findings warrant cautious interpretation given low certainty of evidence. • IMPT and CPT show comparable bilirubin reduction, but prior comparisons relied on limited trials without assessing whether the evidence base is conclusive. • This review incorporates the latest trials, applies Cochrane-guided meta-regression, subgroup, leave-one-out, and Hartung-Knapp sensitivity analyses, and uses TSA to confirm conclusive equivalence across major outcomes.
- 10 July 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (8)
Therapeutic equivalence of intermittent and continuous phototherapy for neonatal jaundice: a systematic review & meta-analysis with regression and trial sequential analysis
Phototherapy is the mainstay treatment for neonatal hyperbilirubinemia, but the optimal delivery strategy remains debated. Intermittent phototherapy (IMPT) has been proposed as an alternative to continuous phototherapy (CPT) that may achieve comparable bilirubin reduction with fewer adverse effects. This systematic review and meta-analysis evaluated the comparative efficacy and safety of IMPT versus CPT in neonates with hyperbilirubinemia. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched through June 2026 for randomized controlled trials comparing IMPT and CPT. Outcomes included rate of fall in bilirubin, follow-up bilirubin, phototherapy duration, hospital stay, and mortality. Random-effects meta-analysis pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Subgroup, meta-regression, and Trial Sequential Analysis (TSA) were performed, and certainty of evidence was graded using GRADE. Twenty-six RCTs (3,891 neonates) were included. No significant difference was found between IMPT and CPT for rate of bilirubin fall, follow-up bilirubin, hospital stay, or mortality. IMPT significantly reduced phototherapy duration (MD - 10.40 h, 95% CI - 18.91 to - 1.88). Heterogeneity was substantial across outcomes. TSA indicated conclusive evidence of equivalence for bilirubin-related and hospital stay outcomes, while evidence for the duration reduction had not yet reached the required information size. Certainty of evidence ranged from low to very low. IMPT achieves outcomes comparable to CPT while significantly reducing treatment duration, supporting its use as a time-efficient alternative, though findings warrant cautious interpretation given low certainty of evidence. • IMPT and CPT show comparable bilirubin reduction, but prior comparisons relied on limited trials without assessing whether the evidence base is conclusive. • This review incorporates the latest trials, applies Cochrane-guided meta-regression, subgroup, leave-one-out, and Hartung-Knapp sensitivity analyses, and uses TSA to confirm conclusive equivalence across major outcomes.